Gain Therapeutics, Inc.
General ticker "GANX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $77.5M (TTM average)
Gain Therapeutics, Inc. follows the US Stock Market performance with the rate: 4.8%.
Estimated limits based on current volatility of 2.8%: low 1.61$, high 1.71$
Factors to consider:
- Total employees count: 21 (-16.0%) as of 2025
- Top business risk factors: Going concern doubt, Need for additional capital, Regulatory and compliance, Limited operating history, Clinical trial failure
- Current price 12.9% below estimated low
- Earnings for 3 months up through Q1 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.96$, 5.12$]
- 2026-12-31 to 2027-12-31 estimated range: [1.67$, 4.43$]
Financial Metrics affecting the GANX estimates:
- Positive: with PPE of -5.1 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 81.36 > 64.23
Short-term GANX quotes
Long-term GANX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.06MM | $0.00MM | $0.00MM |
| Operating Expenses | $22.31MM | $20.35MM | $18.71MM |
| Operating Income | $-22.25MM | $-20.35MM | $-18.71MM |
| Non-Operating Income | $0.06MM | $0.48MM | $-0.59MM |
| R&D Expense | $11.52MM | $10.79MM | $10.21MM |
| Income(Loss) | $-22.19MM | $-19.87MM | $-19.30MM |
| Taxes | $0.08MM | $0.54MM | $0.86MM |
| Net Income(Loss)* | $-22.27MM | $-20.41MM | $-20.16MM |
| Stockholders Equity | $12.58MM | $7.34MM | $18.56MM |
| Assets | $18.61MM | $12.12MM | $22.82MM |
| Operating Cash Flow | $-18.87MM | $-18.87MM | $-18.47MM |
| Capital expenditure | $0.02MM | $0.02MM | $0.00MM |
| Investing Cash Flow | $10.22MM | $4.98MM | $0.00MM |
| Financing Cash Flow | $12.64MM | $13.01MM | $28.45MM |
| Earnings Per Share** | $-1.71 | $-0.89 | $-0.61 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.